Zum Hauptinhalt springen

Naltrexon

25. November 2021 | Naltrexon

Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up

Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up Gaulen, Zhanna et al. Journal of Substance Abuse Treatment, Volume 0, Issue 0, 108656…

12. November 2021 | Naltrexon

Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.

Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial. Roache, J.D., Pavlicova, M., Campbell, A., Choo…

09. November 2021 | Naltrexon

Levels of Impulsivity, Hyperactivity, and Inattention and the Association with Mental Health and Substance Use Severity in Opioid-Dependent Patients Seeking Treatment with Extended-Release Naltrexone.

Levels of Impulsivity, Hyperactivity, and Inattention and the Association with Mental Health and Substance Use Severity in Opioid-Dependent Patients Seeking Treatment with Extended-Release Naltrexone. Karlsson AT, Vederhus JK, Clausen T, Weim…

09. November 2021 | Naltrexon

Low-Dose Naltrexone Co-Treatment in the Prevention of Opioid-Induced Hyperalgesia.

Low-Dose Naltrexone Co-Treatment in the Prevention of Opioid-Induced Hyperalgesia. Shaheed G, Manjooran AP, Reddy AJ, Nawathey N, Habib S, Brahmbhatt H. Cureus. 2021 Sep 2;13(9):e17667. doi: 10.7759/cureus.17667. PMID: 34646707; PMCID…

09. November 2021 | Naltrexon

The impact of age and genetics on naltrexone biotransformation.

The impact of age and genetics on naltrexone biotransformation. Stancil SL, Nolte W, Pearce RE, Staggs VS PhD, Leeder JS. Drug Metab Dispos. 2021 Nov 2:DMD-AR-2021-000646. doi: 10.1124/dmd.121.000646. Epub ahead of print. PMID: 3472851…

15. Juli 2021 | Naltrexon

Adverse drug reactions with naltrexone: Experience from an addiction treatment center.

Adverse drug reactions with naltrexone: Experience from an addiction treatment center. Sarkar S, Addagadda SS, Bhatia G, Chadda RK. Indian J Psychiatry. 2021 Mar-Apr;63(2):206-207. doi: 10.4103/psychiatry.IndianJPsychiatry_94_20. Epub…

08. Juni 2021 | Naltrexon

Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial. (2)

Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial. Kosten T, Aharonovich E…

Weitere Beiträge ansehen

Weitere
akutelle Informationen
zu den Themengebieten